blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2481401

EP2481401 - Lipophilic microparticles containing a protein drug or antigen and formulation comprising same [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.04.2014
Database last updated on 02.11.2024
Most recent event   Tooltip18.04.2014Application deemed to be withdrawnpublished on 21.05.2014  [2014/21]
Applicant(s)For all designated states
LG Life Sciences, Ltd.
20, Yoido-dong, Youngdungpo-gu
Seoul 150-721 / KR
[2012/31]
Inventor(s)01 / Kim, Myung, Jin
c/o LG Life Sciences Ltd.
Research & Development Park
104-1, Moonji-dong, Yuseon-gu
Daejeon 305-380 / KR
02 / Kim, Sun, Jin
c/o LG Life Sciences Ltd.
Research & Development Park
104-1, Moonji-dong, Yuseon-gu
Daejeon 305-380 / KR
03 / Kwon, Kyu, Chan
c/o LG Life Sciences Ltd.
Research & Development Park
104-1, Moonji-dong, Yuseon-gu
Daejeon 305-380 / KR
04 / Kim, Joon
c/o LG Life Sciences Ltd.
Research & Development Park
104-1, Moonji-dong, Yuseon-gu
Daejeon 305-380 / KR
 [2012/33]
Representative(s)Krauss, Jan
Boehmert & Boehmert
Anwaltspartnerschaft mbB
Pettenkoferstrasse 22
80336 München / DE
[N/P]
Former [2012/31]Krauss, Jan
Boehmert & Boehmert
Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date11176647.314.01.2000
[2012/31]
Priority number, dateKR1999000123218.01.1999         Original published format: KR 19990001232
KR1999005977621.12.1999         Original published format: KR 19990059776
[2012/31]
Previously filed application, dateWO2000KR0002514.01.2000
[2012/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2481401
Date:01.08.2012
Language:EN
[2012/31]
Search report(s)(Supplementary) European search report - dispatched on:EP02.07.2012
ClassificationIPC:A61K9/50, A61K38/00, A61K39/00, A61K9/10, A61K9/113, A61K9/16, A61K38/21, A61K39/39, A61K38/27
[2012/31]
CPC:
A61K38/212 (EP); A61K38/27 (EP); A61K39/39 (EP);
A61K9/10 (EP); A61K9/113 (EP); A61K9/1617 (EP);
A61K9/1652 (EP); A61K9/1658 (EP); A61K9/5015 (EP);
A61P31/04 (EP); A61P31/06 (EP); A61P31/10 (EP);
A61P31/14 (EP); A61P31/16 (EP); A61P31/20 (EP);
A61P33/02 (EP); A61P5/50 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2012/31]
TitleGerman:Lipophile Mikropartikel mit einem Proteinarzneimittel oder Antigen und Formulierung damit[2012/31]
English:Lipophilic microparticles containing a protein drug or antigen and formulation comprising same[2012/31]
French:Microparticules lipophiles contenant un médicament à base de protéine ou un antigène et formulation les comprenant[2012/31]
Examination procedure30.01.2013Amendment by applicant (claims and/or description)
30.01.2013Examination requested  [2013/11]
21.05.2013Despatch of a communication from the examining division (Time limit: M06)
03.12.2013Application deemed to be withdrawn, date of legal effect  [2014/21]
15.01.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2014/21]
Parent application(s)   TooltipEP00900954.9  / EP1071407
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000900954) is  07.08.2009
Fees paidRenewal fee
05.08.2011Renewal fee patent year 03
05.08.2011Renewal fee patent year 04
05.08.2011Renewal fee patent year 05
05.08.2011Renewal fee patent year 06
05.08.2011Renewal fee patent year 07
05.08.2011Renewal fee patent year 08
05.08.2011Renewal fee patent year 09
05.08.2011Renewal fee patent year 10
05.08.2011Renewal fee patent year 11
05.08.2011Renewal fee patent year 12
11.01.2012Renewal fee patent year 13
28.01.2013Renewal fee patent year 14
Penalty fee
Additional fee for renewal fee
31.01.201415   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US5059421  (LOUGHREY HELEN C [CA], et al) [A] 1-15 * examples, claims *;
 [X]EP0485143  (NACIONAL DE ENGENHARIA E TECNO [PT]) [X] 1-15 * examples, claims *;
 [Y]WO9214449  (NOVA PHARM CORP [US]) [Y] 1-15 * examples, claims, esp. claim 8 *;
 [X]DE4107153  (CEVC GREGOR [DE]) [X] 1-15 * examples, claims *;
 [Y]WO9512385  (ISOTECH MEDICAL INC [US], et al) [Y] 1-15 * claims,esp. claim 30, examples *;
 [A]WO9813024  (HYAL PHARMA CORP [CA], et al) [A] 1-15 * examples, claims *;
 [X]WO9829099  (BIOVECTOR THERAPEUTICS SA [FR]) [X] 1-15 * examples, claims *;
 [X]WO9843664  (LG CHEMICAL LTD [KR], et al) [X] 1-15 * examples, claims, esp. claim 10 *;
 [A]US5858398  (CHO YOUNG W [US]) [A] 1-15 * the whole document *;
 [L]WO0209674  (ALLIANCE PHARMA [US], et al) [L] 1-15* the whole document *
by applicantJPH01287041
 JPH022213
 US5416017
 US5753234
    - WEIQI LU ET AL., PDA J. PHARM. SCI. TECH., (1995), vol. 49, pages 13 - 19
    - HELLER, J., ADV. DRUG DEL. REV., (1993), vol. 10, page 163
    - PARK, T. G. ET AL., J. CONTROL. REL., (1995), vol. 33, pages 211 - 223
    - LEE, H. K. ET AL., J. CONTROL. REL., (1997), vol. 44, pages 283 - 294
    - MEYER, J. ET AL., J. CONTROLLED REL., (1995), vol. 35, page 67
    - NIGHTLINGER, N.S. ET AL., PROCEED. INTERN. SYMP. CONTROL REL. BIOACT. MATER., (1995), page 3205
    - ILUM, L. ET AL., J. CONTROLLED REL., (1994), vol. 29, page 133
    - LEE, V. H. L., CRIT. REV. THER. DRUG CARRIER SYSTEMS, (1988), vol. 5, pages 69 - 97
    - YOSHIOKA, S. ET AL., J. PHARM. SCI., (1982), vol. 71, pages 593 - 597
    - SCOTT-MONCRIEFF, J. C. ET AL., J. PHARM. SCI., (1994), vol. 83, pages 1465 - 1469
    - MURANISHI, S. ET AL., CHEM. PHARM. BULL., (1977), vol. 25, pages 1159 - 1163
    - FIX, J. A. ET AL., AM. J. PHYSIOL., (1986), vol. 251, pages G332 - G340
    - SHAO, Z. ET AL., PHARM. RES., (1993), vol. 1, no. 0, pages 143 - 250
    - CONSTANTINIDES, P. P ET AL., PROC. INT. SYMP. CONTROL. RELEASE BIOACTIVE MATER., (1993), vol. 20, pages 184 - 185
    - BJORK, E. ET AL., J. DRUG TARGETING, (1995), vol. 2, pages 501 - 507
    - GENCO, R. ET AL., ANN. N. Y. ACAD. SCI., (1983), vol. 409, pages 650 - 667
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.